We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Researchers from the Wellcome Sanger Institute have identified a new genetic target, which is linked with poor prognosis, for the potential treatment of acute myeloid leukaemia (AML) – a type of blood cancer.